Toutes les photos(2)

Key Documents

COO/COA

View All Documentation

GF33100298

Yttrium

Name: Yttrium
Brand: ALDRICH

foil, not light tested, 100x100mm, thickness 0.025mm, as rolled, 99%

Synonyme(s) :

Yttrium, Y 000200

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(2)

About This Item

Formule empirique (notation de Hill):

Numéro CAS:

7440-65-5

Poids moléculaire :

88.91

Numéro MDL:

MFCD00011468

Code UNSPSC :

12141617

ID de substance PubChem :

329805022

Nomenclature NACRES :

NA.23

Pureté

99%

Forme

foil

Fabricant/nom de marque

Goodfellow 331-002-98

Résistivité

57 μΩ-cm, 20°C

Taille × épaisseur

100x100 mm × 0.025 mm

Point d'ébullition

3338 °C (lit.)

Pf

1522 °C (lit.)

Densité

4.469 g/mL at 25 °C (lit.)

Chaîne SMILES

[Y]

InChI

1S/Y

Clé InChI

VWQVUPCCIRVNHF-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

For updated SDS information please visit www.goodfellow.com.

Informations légales

Product of Goodfellow

Code de la classe de stockage

13 - Non Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.

Aki Aoyama et al.

Molecular cancer therapeutics, 13(12), 2978-2990 (2014-10-15)

Tivantinib (ARQ197) was first reported as a highly selective inhibitor of c-MET and is currently being investigated in a phase III clinical trial. However, as recently reported by us and another group, tivantinib showed cytotoxic activity independent of cellular c-MET

Development of Desolvation System for Single-cell Analysis Using Droplet Injection Inductively Coupled Plasma Atomic Emission Spectroscopy.

Yukiko Ishihara et al.

Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 31(8), 781-785 (2015-08-11)

With a view to enhance the sensitivity of analytical instruments used in the measurement of trace elements contained in a single cell, we have now equipped the previously reported micro-droplet injection system (M-DIS) with a desolvation system. This modified M-DIS

Nanoscopic yttrium oxide fluorides: non-aqueous fluorolytic sol-gel synthesis and structural insights by 19F and 89Y MAS NMR.

G Scholz et al.

Dalton transactions (Cambridge, England : 2003), 44(30), 13522-13529 (2015-07-03)

Nanoscopic yttrium acetate fluorides Y(CH(3)COO)(3-z)F(z) and yttrium oxide fluorides YO(3-z)/(2)F(z )were prepared with tunable Y/F molar ratios via the fluorolytic sol-gel route. All samples were characterized by X-ray diffraction, elemental analysis and thermal analysis. In addition, local structures of all

Alpha-NaYF4:Nd3+ nanocrystal with near-infrared to near-infrared luminescence for bioimaging applications.

Xue Wang et al.

Journal of nanoscience and nanotechnology, 14(5), 3910-3913 (2014-04-17)

Nd3+ doped alpha-NaYF4 nanocrystals with size of about 15 nm were successfully synthesized through hydrothermal method. Nearly pure near-infrared to near-infrared (NIR-to-NIR) luminescence can be realized. Moreover, the excitation and the emission at 880 and 1060 nm, respectively, are away

Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization.

Ryan Hickey et al.

International journal of radiation oncology, biology, physics, 88(5), 1025-1031 (2014-03-26)

Radiosensitizing chemotherapy improves the outcomes in comparison with radiation alone for gastrointestinal cancers. The delivery of radiation therapy with yttrium90 ((90)Y) radioembolization, in combination with the radiosensitizing chemotherapeutic agent capecitabine, provides the opportunity to enhance the effects of radiation on

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique